vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
RBC Bearings INC的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.1倍（$461.6M vs $406.6M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs 14.6%，领先45.9%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 17.0%），BIOCRYST PHARMACEUTICALS INC自由现金流更多（$291.2M vs $99.1M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 5.6%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
BCRX vs RBC — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $461.6M |
| 净利润 | $245.8M | $67.4M |
| 毛利率 | 97.7% | 44.3% |
| 营业利润率 | 64.0% | 22.3% |
| 净利率 | 60.5% | 14.6% |
| 营收同比 | 209.1% | 17.0% |
| 净利润同比 | 1017.5% | 16.4% |
| 每股收益（稀释后） | $1.13 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $406.6M | $461.6M | ||
| Q3 25 | $159.4M | $455.3M | ||
| Q2 25 | $163.4M | $436.0M | ||
| Q1 25 | $145.5M | $437.7M | ||
| Q4 24 | $131.5M | $394.4M | ||
| Q3 24 | $117.1M | $397.9M | ||
| Q2 24 | $109.3M | $406.3M | ||
| Q1 24 | $92.8M | $413.7M |
| Q4 25 | $245.8M | $67.4M | ||
| Q3 25 | $12.9M | $60.0M | ||
| Q2 25 | $5.1M | $68.5M | ||
| Q1 25 | $32.0K | $72.7M | ||
| Q4 24 | $-26.8M | $57.9M | ||
| Q3 24 | $-14.0M | $54.2M | ||
| Q2 24 | $-12.7M | $61.4M | ||
| Q1 24 | $-35.4M | — |
| Q4 25 | 97.7% | 44.3% | ||
| Q3 25 | 98.6% | 44.1% | ||
| Q2 25 | 98.3% | 44.8% | ||
| Q1 25 | 96.9% | 44.2% | ||
| Q4 24 | 95.4% | 44.3% | ||
| Q3 24 | 97.3% | 43.7% | ||
| Q2 24 | 98.4% | 45.3% | ||
| Q1 24 | 98.6% | 43.1% |
| Q4 25 | 64.0% | 22.3% | ||
| Q3 25 | 18.6% | 21.5% | ||
| Q2 25 | 18.2% | 23.2% | ||
| Q1 25 | 14.6% | 23.0% | ||
| Q4 24 | -3.4% | 21.7% | ||
| Q3 24 | 6.6% | 21.6% | ||
| Q2 24 | 8.0% | 24.0% | ||
| Q1 24 | -15.6% | 22.8% |
| Q4 25 | 60.5% | 14.6% | ||
| Q3 25 | 8.1% | 13.2% | ||
| Q2 25 | 3.1% | 15.7% | ||
| Q1 25 | 0.0% | 16.6% | ||
| Q4 24 | -20.4% | 14.7% | ||
| Q3 24 | -12.0% | 13.6% | ||
| Q2 24 | -11.6% | 15.1% | ||
| Q1 24 | -38.1% | — |
| Q4 25 | $1.13 | $2.13 | ||
| Q3 25 | $0.06 | $1.90 | ||
| Q2 25 | $0.02 | $2.17 | ||
| Q1 25 | $0.00 | $2.33 | ||
| Q4 24 | $-0.13 | $1.82 | ||
| Q3 24 | $-0.07 | $1.65 | ||
| Q2 24 | $-0.06 | $1.90 | ||
| Q1 24 | $-0.17 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $107.6M |
| 总债务越低越好 | — | $990.2M |
| 股东权益账面价值 | $-119.2M | $3.3B |
| 总资产 | $514.2M | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
| Q4 25 | $274.7M | $107.6M | ||
| Q3 25 | $212.9M | $91.2M | ||
| Q2 25 | $260.0M | $132.9M | ||
| Q1 25 | $295.1M | $36.8M | ||
| Q4 24 | $320.9M | — | ||
| Q3 24 | $96.8M | — | ||
| Q2 24 | $78.4M | $76.8M | ||
| Q1 24 | $84.3M | $63.5M |
| Q4 25 | — | $990.2M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $915.6M | ||
| Q1 25 | — | $920.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $-119.2M | $3.3B | ||
| Q3 25 | $-387.9M | $3.2B | ||
| Q2 25 | $-421.6M | $3.1B | ||
| Q1 25 | $-451.9M | $3.0B | ||
| Q4 24 | $-475.9M | $2.9B | ||
| Q3 24 | $-468.6M | $2.9B | ||
| Q2 24 | $-475.6M | $2.8B | ||
| Q1 24 | $-476.2M | $2.8B |
| Q4 25 | $514.2M | $5.1B | ||
| Q3 25 | $446.4M | $5.1B | ||
| Q2 25 | $457.2M | $4.8B | ||
| Q1 25 | $480.0M | $4.7B | ||
| Q4 24 | $490.4M | $4.7B | ||
| Q3 24 | $491.3M | $4.7B | ||
| Q2 24 | $472.4M | $4.7B | ||
| Q1 24 | $467.9M | $4.7B |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $99.1M |
| 自由现金流率自由现金流/营收 | 71.6% | 21.5% |
| 资本支出强度资本支出/营收 | 0.2% | 5.0% |
| 现金转化率经营现金流/净利润 | 1.19× | 1.81× |
| 过去12个月自由现金流最近4个季度 | $344.9M | — |
8季度趋势，按日历期对齐
| Q4 25 | $292.0M | $122.1M | ||
| Q3 25 | $41.6M | $88.4M | ||
| Q2 25 | $41.3M | $120.0M | ||
| Q1 25 | $-27.5M | — | ||
| Q4 24 | $-5.2M | $84.0M | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.4M | $97.4M | ||
| Q1 24 | $-53.7M | — |
| Q4 25 | $291.2M | $99.1M | ||
| Q3 25 | $40.3M | $71.7M | ||
| Q2 25 | $41.1M | $104.3M | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-5.9M | $73.6M | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.5M | $88.4M | ||
| Q1 24 | $-53.9M | — |
| Q4 25 | 71.6% | 21.5% | ||
| Q3 25 | 25.3% | 15.7% | ||
| Q2 25 | 25.2% | 23.9% | ||
| Q1 25 | -19.0% | — | ||
| Q4 24 | -4.5% | 18.7% | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | -1.4% | 21.8% | ||
| Q1 24 | -58.1% | — |
| Q4 25 | 0.2% | 5.0% | ||
| Q3 25 | 0.8% | 3.7% | ||
| Q2 25 | 0.1% | 3.6% | ||
| Q1 25 | 0.1% | 3.2% | ||
| Q4 24 | 0.5% | 2.6% | ||
| Q3 24 | 0.1% | 4.1% | ||
| Q2 24 | 0.1% | 2.2% | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 1.19× | 1.81× | ||
| Q3 25 | 3.23× | 1.47× | ||
| Q2 25 | 8.12× | 1.75× | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.59× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
暂无分部数据
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
